Division of Animal Sciences, University of Missouri, Columbia, Missouri, USA.
PLoS One. 2013 May 29;8(5):e61000. doi: 10.1371/journal.pone.0061000. Print 2013.
Spermatid specific thioredoxin-3 (SPTRX3 or TXNDC8) is a testis/male germ line specific member of thioredoxin family that accumulates in the superfluous cytoplasm of defective human spermatozoa. We hypothesized that semen levels of SPTRX3 are reflective of treatment outcome in assisted reproductive therapy (ART) couples treated by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Relationship between SPTRX3 and treatment outcome was investigated in 239 couples undergoing ART at an infertility clinic. Sperm content of SPTRX3 was evaluated by flow cytometry and epifluorescence microscopy, and correlated with clinical semen analysis parameters, and data on embryo development and pregnancy establishment. High SPTRX3 levels (>15% SPTRX3-positive spermatozoa) were found in 51% of male infertility patients (n = 72), in 20% of men from couples with unexplained, idiopathic infertility (n = 61) and in 14% of men from couples previously diagnosed with female-only infertility (n = 85). Couples with high SPTRX3 produced fewer two-pronuclear zygotes and had a reduced pregnancy rate (19.2% pregnant with >15% SPTRX3-positive spermatozoa vs. 41.2% pregnant with <5% SPTRX3-positive sperm; one-sided p<0.05). The average pregnancy rate of all 239 couples was 25.1%. Live birth rate was 19.2% and lowest average SPTRX3 levels were found in couples that delivered twins. Men with >15% of SPTRX3-positive spermatozoa, a cutoff value established by ROC analysis, had their chance of fathering children by IVF or ICSI reduced by nearly two-thirds. The percentage of SPTRX3-positive spermatozoa had predictive value for pregnancy after ART. Gradient purification and sperm swim-up failed to remove all SPTRX3-positive spermatozoa from semen prepared for ART. In summary, the elevated semen content of SPTRX3 in men from ART couples coincided with reduced incidence of pregnancy by IVF or ICSI, identifying SPTRX3 as a candidate biomarker reflective of ART outcome.
精子特异性硫氧还蛋白 3(SPTRX3 或 TXNDC8)是硫氧还蛋白家族中睾丸/男性生殖细胞特异性成员,在有缺陷的人类精子过多的细胞质中积累。我们假设精液中 SPTRX3 的水平反映了接受体外受精(IVF)或胞浆内精子注射(ICSI)治疗的辅助生殖治疗(ART)夫妇的治疗结果。我们在一家不孕不育诊所接受 ART 的 239 对夫妇中研究了 SPTRX3 与治疗结果之间的关系。通过流式细胞术和荧光显微镜评估精子中 SPTRX3 的含量,并将其与临床精液分析参数以及胚胎发育和妊娠建立的数据相关联。在 51%的男性不育患者(n=72)、20%的不明原因、特发性不孕夫妇中的男性(n=61)和 14%的先前诊断为女性不孕的夫妇中的男性(n=85)中发现高 SPTRX3 水平(>15%SPTRX3 阳性精子)。高 SPTRX3 的夫妇产生的双原核受精卵较少,妊娠率降低(>15%SPTRX3 阳性精子的妊娠率为 19.2%,<5%SPTRX3 阳性精子的妊娠率为 41.2%;单侧 p<0.05)。239 对夫妇的平均妊娠率为 25.1%。活产率为 19.2%,双胞胎分娩夫妇的平均 SPTRX3 水平最低。通过 ROC 分析确定的截断值(>15%SPTRX3 阳性精子)的男性通过 IVF 或 ICSI 生育的机会减少了近三分之二。SPTRX3 阳性精子的百分比对 ART 后妊娠有预测价值。梯度纯化和精子泳动未能从用于 ART 的精液中去除所有 SPTRX3 阳性精子。总之,ART 夫妇的精子中 SPTRX3 含量升高与 IVF 或 ICSI 妊娠率降低相吻合,表明 SPTRX3 是反映 ART 结果的候选生物标志物。